- Home
- XPEV vs RPRX Comparison
XPEV vs RPRX Comparison
Compare XPEV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEV
- RPRX
- Stock Information
- Founded
- XPEV 2015
- RPRX 1996
- Country
- XPEV China
- RPRX United States
- Employees
- XPEV N/A
- RPRX N/A
- Industry
- XPEV Auto Manufacturing
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- XPEV Consumer Discretionary
- RPRX Health Care
- Exchange
- XPEV Nasdaq
- RPRX Nasdaq
- Market Cap
- XPEV 12.0B
- RPRX 14.0B
- IPO Year
- XPEV 2020
- RPRX 2020
- Fundamental
- Price
- XPEV $18.43
- RPRX $33.42
- Analyst Decision
- XPEV Buy
- RPRX Strong Buy
- Analyst Count
- XPEV 8
- RPRX 6
- Target Price
- XPEV $13.84
- RPRX $41.67
- AVG Volume (30 Days)
- XPEV 10.5M
- RPRX 4.6M
- Earning Date
- XPEV 03-18-2025
- RPRX 02-11-2025
- Dividend Yield
- XPEV N/A
- RPRX 2.63%
- EPS Growth
- XPEV N/A
- RPRX N/A
- EPS
- XPEV N/A
- RPRX 1.91
- Revenue
- XPEV $5,390,497,248.00
- RPRX $2,263,576,000.00
- Revenue This Year
- XPEV $36.03
- RPRX $29.18
- Revenue Next Year
- XPEV $74.22
- RPRX $9.99
- P/E Ratio
- XPEV N/A
- RPRX $17.52
- Revenue Growth
- XPEV 66.09
- RPRX N/A
- 52 Week Low
- XPEV $6.55
- RPRX $24.05
- 52 Week High
- XPEV $19.36
- RPRX $33.69
- Technical
- Relative Strength Index (RSI)
- XPEV 69.24
- RPRX 78.16
- Support Level
- XPEV $17.46
- RPRX $32.28
- Resistance Level
- XPEV $18.29
- RPRX $33.69
- Average True Range (ATR)
- XPEV 0.70
- RPRX 0.69
- MACD
- XPEV 0.11
- RPRX -0.02
- Stochastic Oscillator
- XPEV 79.78
- RPRX 89.85
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.